Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

The exact cause of psoriatic arthritis isn't known, but the immune system plays a major role in its development. In general, ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

In the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), a total of 54 sites on radiographs of the hands and feet were evaluated for erosions, and 48 sites were evaluated for JSN. [24] ...

Metabolic syndrome affects more than 58% of patients with psoriatic arthritis and is correlated with “degenerative and metabolic changes in the spine and entheses,” according to data published ...

Provided by PR NewswireJun 11, 2025, 4:16:00 PM BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial ...

Is there a benefit to early bDMARD? — In psoriatic arthritis (PsA) EULAR – The European Alliance of Associations for Rheumatology – recommends a treat-to-target approach, and suggests more ...

Deucravacitinib significantly improved joint and skin symptoms, disease activity, and quality of life in psoriatic arthritis patients. The trials demonstrated sustained clinical responses through ...

Is there a benefit to early bDMARD? In psoriatic arthritis (PsA) EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more intensive ...